NCT04923906 2024-11-25
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT04687241 2024-11-07
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04685070 2024-08-14
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting